| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S12016-008-8099-5 |
| P698 | PubMed publication ID | 18987784 |
| P2093 | author name string | Paul R J Ames | |
| Annamaria Margarita | |||
| Jose Delgado Alves | |||
| P2860 | cites work | Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity | Q22010527 |
| The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA | Q24300736 | ||
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids | Q28678353 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus | Q33329033 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients | Q33363684 | ||
| The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68 | Q33854305 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus | Q34897464 | ||
| Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome | Q35552883 | ||
| Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence | Q35860978 | ||
| Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury | Q36007691 | ||
| Impact of oxidized low density lipoprotein on vascular cells | Q36313378 | ||
| Oxidized low-density lipoprotein biomarkers in atherosclerosis | Q36385153 | ||
| NF-kappaB activation by reactive oxygen species: fifteen years later | Q36488422 | ||
| Antibodies against beta2-glycoprotein I complexed with an oxidised lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome. | Q36502225 | ||
| Apolipoprotein A-I and risk for cardiovascular diseases | Q36562244 | ||
| Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. | Q36590099 | ||
| Statins and the vascular endothelial inflammatory response | Q36695979 | ||
| The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia | Q36791429 | ||
| Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment? | Q36812952 | ||
| Absence of Chlamydia pneumoniae and signs of atherosclerotic cardiovascular disease in adolescents with systemic lupus erythematosus | Q37858489 | ||
| A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages | Q40806151 | ||
| Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease | Q41673431 | ||
| Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies | Q43742774 | ||
| Risk factors for cardiovascular disease in systemic lupus erythematosus | Q43767819 | ||
| Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies | Q44013915 | ||
| Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome | Q44183283 | ||
| Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen | Q44300088 | ||
| Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. | Q44412972 | ||
| Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. | Q46184001 | ||
| Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease? | Q46309832 | ||
| Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome | Q46367698 | ||
| Urinary 8-epi-PGF2alpha and its endogenous beta-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress | Q46421035 | ||
| Rituximab treatment for resistant antiphospholipid syndrome. | Q46427705 | ||
| Relationship between oxidative stress and essential hypertension | Q46698561 | ||
| Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus | Q46724748 | ||
| Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus | Q46973423 | ||
| Subclinical atherosclerosis in primary antiphospholipid syndrome | Q46982844 | ||
| Antiphospholipid antibodies in vascular surgery patients. A cross-sectional study | Q47221331 | ||
| IgG-anticardiolipin-antibodies are markers for cerebral and peripheral artery disease | Q48558924 | ||
| The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease. | Q51500234 | ||
| Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. | Q51563585 | ||
| Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study. | Q52553689 | ||
| A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. | Q53598537 | ||
| Scavenger cell receptor shared. | Q54232301 | ||
| Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus | Q60709702 | ||
| Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein | Q68247652 | ||
| Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes | Q69063844 | ||
| Vasculopathy in the antiphospholipid syndrome: thrombosis or vasculitis, or both? | Q69231988 | ||
| Antiphospholipid arterial vasculopathy | Q69725515 | ||
| Lupus anticoagulant in patients with peripheral vascular disease: a prospective study | Q71914828 | ||
| Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages | Q73149303 | ||
| Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study | Q73491960 | ||
| Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus | Q73904664 | ||
| Are antiphospholipid antibodies an independent risk factor for atherosclerosis? | Q74469930 | ||
| Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein | Q77871796 | ||
| Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus | Q77909409 | ||
| Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome | Q79375391 | ||
| Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus | Q79376053 | ||
| Carotid intima-media thickness, plaques, and Framingham risk score as independent determinants of stroke risk | Q80379010 | ||
| Atherosclerosis is accelerated in patients with long-term well-controlled systemic lupus erythematosus (SLE) | Q80650267 | ||
| Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome | Q80725362 | ||
| Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab--monitoring of antiphospholipid and anti-GP antibodies: a case report | Q81489401 | ||
| Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding | Q81541158 | ||
| Recruitment of beta-2-glycoprotein 1 to cell surfaces in extrinsic and intrinsic apoptosis | Q81672818 | ||
| Integrated backscatter analysis of carotid intima-media complex in patients with systemic lupus erythematosus | Q81698497 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| antibody | Q79460 | ||
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 29-35 | |
| P577 | publication date | 2009-08-01 | |
| P1433 | published in | Clinical Reviews in Allergy & Immunology | Q1932354 |
| P1476 | title | Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome | |
| P478 | volume | 37 |
| Q55279180 | A importância de reconhecer a síndrome antifosfolípide na medicina vascular. |
| Q47623831 | A role for autoantibodies in atherogenesis |
| Q38410376 | Antiphospholipid syndrome: an update |
| Q37378106 | Atherosclerosis in autoimmune diseases |
| Q27016554 | Cardiovascular disease in lupus: insights and updates |
| Q34003460 | Cardiovascular risk factors in the antiphospholipid syndrome |
| Q37853050 | Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome |
| Q38078691 | Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases |
| Q86737884 | Does the presence of secondary antiphospholipid syndrome in patients with systemic lupus erythematodes accelerate carotid arteries intima-media thickness changes? |
| Q35029916 | Dyslipidaemia in rheumatological autoimmune diseases |
| Q33937755 | Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease |
| Q92369603 | Interleukin-17/Interleukin-21 and Interferon-γ producing T cells specific for β2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome |
| Q46339090 | Long-term outcome of patients with antiphospholipid syndrome who undergo percutaneous coronary intervention |
| Q38024789 | New Insights into the Molecular Basis of the Antiphospholipid Syndrome |
| Q33414595 | Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome |
| Q37137892 | Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy |
| Q91854110 | Primary Antiphospholipid Antibody Syndrome Complicated with Cerebellar Hemorrhage and Aortic Dissection: A Case Report |
| Q54336169 | Role of Toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. |
| Q37817582 | The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? |
| Q48243949 | β2 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome |
Search more.